MT2 10 MG

What is Melanotan II (MT-2)?

Melanotan II (MT-2) is a synthetic peptide analog of alpha-melanocyte-stimulating hormone (α-MSH). It was originally developed for research into skin pigmentation and photoprotection, but has also been studied for its effects on sexual function through activation of melanocortin receptors. It is not approved by the U.S. FDA for cosmetic tanning or general medical use.

What is it studied for?

Research involving MT-2 has explored several areas:

• Skin pigmentation (tanning): It stimulates melanin production, increasing skin pigmentation and reducing the UV exposure needed to achieve a tan.
• Photoprotection: Investigated as a potential way to increase natural pigmentation that may help protect against UV damage, although it is not approved for this purpose.
• Sexual function: Early studies observed increased erectile responses and libido-related effects, leading to the development of related compounds for sexual dysfunction research. 
• Appetite and body weight regulation: Because melanocortin pathways influence energy balance, MT-2 has been explored experimentally for appetite suppression and weight-related effects.

What is it commonly stacked with in research settings?

Among researchers and enthusiasts, MT-2 is commonly discussed alongside:

• UV light exposure – Many users combine MT-2 with controlled UV exposure because the peptide enhances melanin production but does not completely replace the role of UV in developing a tan.
• PT-141 (Bremelanotide) – Sometimes mentioned due to overlapping melanocortin receptor activity and sexual function research, although PT-141 is a distinct compound.
• GHK-Cu – Occasionally paired in cosmetic or skin-focused research discussions because of interest in skin appearance and repair.
• Epitalon – Sometimes included in broader longevity or skin-health protocols discussed in research communities.
• General skin-support supplements such as antioxidants are also sometimes used by individuals experimenting with tanning regimens, though evidence for combined benefits is limited.